Skip to main content
SpringerLink
Log in

Ghrelin and GHS on cardiovascular applications/functions

  • Short Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Although initially recognised for their GH-releasing properties, the cardiovascular system has been recognised as a potentially important target for GH secretagogues (GHS). Moreover, a limited number of studies also indicate cardiovascular effects of ghrelin. So far reported cardiovascular effects of GHS and/or ghrelin include lowering of peripheral resistance, possible improvement of contractility and cardioprotective effects both in vivo and in vitro. Taken together, these results offer an interesting perspective on the future where further studies aiming at evaluating a role of GHS and ghrelin in the treatment of cardiovascular disease are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bisi G, Podio V, Valetto MR, et al. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest 1999, 22: 266–72.

    Article  CAS  PubMed  Google Scholar 

  2. Bisi G, Podio V, Valetto MR, et al. Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol 1999, 381: 31–8.

    Article  CAS  PubMed  Google Scholar 

  3. Enomoto M, Nagaya N, Uematsu M, et al. Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin Sci (Lond) 2003, 105: 431–5.

    Article  CAS  Google Scholar 

  4. Strömer H, Cittadini A, Douglas PS, Morgan JP. Exogenously administered growth hormone and insulin-like growth factor-I alter intracellular Ca2+ handling and enhance cardiac performance. In vitro evaluation in the isolated isovolumic buffer-perfused rat heart. Circ Res 1996, 79: 227–36.

    Google Scholar 

  5. Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001, 280: R1483–7.

    CAS  PubMed  Google Scholar 

  6. Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002, 136: 1146–52.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. ShimizuY, Nagaya N, Teranishi Y, et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun 2003, 310: 830–5.

    Article  CAS  PubMed  Google Scholar 

  8. Okumura H, Nagaya N, Enomoto M, et al. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 2002, 39: 779–83.

    Article  CAS  PubMed  Google Scholar 

  9. Lin Y, Matsumura K, Fukuhara M, et al. Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 2004, 43: 977–82.

    Article  CAS  PubMed  Google Scholar 

  10. Li WG, Gavrila D, Liu X, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 2004, 109: 2221–6.

    Article  CAS  PubMed  Google Scholar 

  11. De Gennaro Colonna V, Rossoni G, Bernareggi M, et al. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. EurJ Pharmacol 1997, 334: 201–7.

    Article  Google Scholar 

  12. Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 1999, 140: 4024–31.

    CAS  PubMed  Google Scholar 

  13. Weekers F, Van Herck E, Isgaard J, Van den Berghe G. Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model. Endocrinology 2000, 141: 3993–9.

    CAS  PubMed  Google Scholar 

  14. Tivesten A, Bollano E, Caidahl K, et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 2000, 141: 60–6.

    CAS  PubMed  Google Scholar 

  15. King MK, Gay DM, Pan LC, et al. Treatment with a growth hormone secretagogue in a model of developing heart failure: effects on ventricular and myocyte function. Circulation 2001, 103: 308–13.

    Article  CAS  PubMed  Google Scholar 

  16. Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001, 104: 1430–5.

    Article  CAS  PubMed  Google Scholar 

  17. Chang L, Ren Y, Liu X, et al. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol 2004, 43: 165–70.

    Article  CAS  PubMed  Google Scholar 

  18. Broglio F, Benso A, Valetto MR, et al. Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy. Endocrine 2001, 14: 105–8.

    Article  CAS  PubMed  Google Scholar 

  19. Nagaya N, Miyatake K, Uematsu M, et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 2001, 86: 5854–9.

    Article  CAS  PubMed  Google Scholar 

  20. Broglio F, Guarracino F, Benso A, et al. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. Eur J Pharmacol 2002, 448: 193–200.

    Article  CAS  PubMed  Google Scholar 

  21. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004, 110: 3674–9.

    Article  CAS  PubMed  Google Scholar 

  22. Torsello A, Bresciani E, Rossoni G, et al. Ghrelin plays a minor role in the physiological control of cardiacfunction in the rat. Endocrinology 2003, 144: 1787–92.

    Article  CAS  PubMed  Google Scholar 

  23. Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 2002, 90: 844–9.

    Article  CAS  PubMed  Google Scholar 

  24. Pettersson I, Muccioli G, Granata R, et al. Natural (ghrelin) and synthetic (hexarelin) growth hormone secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol 2002, 175: 201–9.

    Article  CAS  PubMed  Google Scholar 

  25. Howard AD, Wang R, Pong SS, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273: 974–7.

    Article  CAS  PubMed  Google Scholar 

  26. Baldanzi G, Cutrupi S, Filigheddu N, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through Erk-1/2 and Pl 3-kinase/akt. J Cell Biol 2002, 159: 1029–37.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Pang JJ, Xu RK, Xu XB, et al. Hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis in vitro. Am J Physiol Heart Circ Physiol 2004, 286: H1063–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Center for Endocrinology and Metabolism, Department of Internal Medicine, Sahlgrenska Academy, University of Göteborg, Gröna Stråket 8, SE-413 45, Göteborg, Sweden

    J. Isgaard MD, PhD & I. Johansson

Authors
  1. J. Isgaard MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Isgaard MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Isgaard, J., Johansson, I. Ghrelin and GHS on cardiovascular applications/functions. J Endocrinol Invest 28, 838–842 (2005). https://doi.org/10.1007/BF03347578

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347578

Key-words

Search

Navigation